Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 19/20 | 0.43 |
| ▸ | UBE2M | P61081 | 1/20 | 0.42 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.42 |
| ▸ | GIPR | P48546 | 8/20 | 0.42 |
| ▸ | GLP1R | P43220 | 3/20 | 0.41 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.41 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.41 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.41 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.41 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.41 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.41 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.41 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.41 |
| ▸ | ADCY4 | Q8NFM4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2645043 | 1.00 | GCGR (0.43) | GCGRUBE2MDCUN1D1GIPRGLP1R | |
| SCHEMBL2643296 | 0.82 | GCGR (0.51) | GCGRGIPRGLP1R | |
| SCHEMBL2651378 | 0.82 | GCGR (0.51) | GCGRGIPRGLP1R | |
| SCHEMBL9071318 | 0.81 | GCGR (0.54) | GCGRGIPRGLP1RADCY6ADCY3 | |
| SCHEMBL2665670 | 0.80 | GCGR (0.57) | GCGRUBE2MDCUN1D1GIPRGLP1R | |
| SCHEMBL2653372 | 0.80 | GCGR (0.67) | GCGRGIPRGLP1RADCY6ADCY3 | |
| SCHEMBL2644178 | 0.80 | GCGR (0.63) | GCGRUBE2MDCUN1D1GIPRGLP1R | |
| SCHEMBL2644176 | 0.80 | GCGR (0.63) | GCGRUBE2MDCUN1D1GIPRGLP1R | |
| SCHEMBL2645044 | 0.79 | PDE2A (0.34) | GCGRGIPR | |
| SCHEMBL2663318 | 0.78 | GCGR (0.65) | GCGRGIPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030203946-A1 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-10-30 | — | — | US | disclosed |
| US-20030203946-A1 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-10-30 | — | — | US | disclosed |
| WO-2002040445-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203946-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GCGR 3/4885UBE2M 4517/4885DCUN1D1 2012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.